MYBL2 Antibody (monoclonal) (M02)
Mouse monoclonal antibody raised against a partial recombinant MYBL2.
|Application ||WB, IF, E|
|Calculated MW||78764 Da|
|Other Names||Myb-related protein B, B-Myb, Myb-like protein 2, MYBL2, BMYB|
|Target/Specificity||MYBL2 (AAH53555, 601 a.a. ~ 700 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||MYBL2 Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene, a member of the MYB family of transcription factor genes, is a nuclear protein involved in cell cycle progression. The encoded protein is phosphorylated by cyclin A/cyclin-dependent kinase 2 during the S-phase of the cell cycle and possesses both activator and repressor activities. It has been shown to activate the cell division cycle 2, cyclin D1, and insulin-like growth factor-binding protein 5 genes. Transcript variants may exist for this gene, but their full-length natures have not been determined.
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Nord H, et al. Int J Cancer, 2010 Mar 15. PMID 19821490.Genetic susceptibility to distinct bladder cancer subphenotypes. Guey LT, et al. Eur Urol, 2010 Feb. PMID 19692168.PTEN identified as important risk factor of chronic obstructive pulmonary disease. Hosgood HD 3rd, et al. Respir Med, 2009 Dec. PMID 19625176.B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells. Mannefeld M, et al. Cancer Res, 2009 May 1. PMID 19383908.Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. Shen M, et al. Environ Mol Mutagen, 2009 May. PMID 19170196.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.